Evidence map›Paper›PMID 34090707›Full record

ArticleGynecologic oncology2021

Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.

Gillian E Hanley, Paramdeep Kaur, Andrew Berchuck, Anne Chase, Bronwyn Grout, Cindy McKinnon Deurloo, Malcolm Pike, Jean Richardson, Kathryn L Terry, Penelope M Webb and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Statins as Repurposed Drugs in Gynecological Cancer: A Review.International journal of molecular sciences · 2022
    Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 3 countries.

Gillian E HanleyDepartment of Gynaecology and Obstetrics, Division of Gynaecologic Oncology, University of British Columbia, Vancouver, BC, Canada. Electronic address: Gillian.hanley@vch.ca.
Paramdeep KaurDepartment of Gynaecology and Obstetrics, Division of Gynaecologic Oncology, University of British Columbia, Vancouver, BC, Canada.
Andrew BerchuckDepartment of Gynecologic Oncology, Duke University Medical Center, Durham, NC, United States.
Anne ChaseRegina, SK, Canada.
Bronwyn GroutSydney, NSW, Australia.
Cindy McKinnon DeurlooEast Hampstead, NH, United States.
Malcolm PikeMemorial Sloan Kettering, New York, NY, United States; Department of Preventive Medicine, University of Southern California, Los Angeles, CA, United States.
Jean RichardsonDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA, United States.
Kathryn L TerryDepartment of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, United States; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Penelope M WebbPopulation Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
C Leigh PearceDepartment of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, United States.
University of British Columbia · CADuke Medical Center · USHarvard University · USMemorial Sloan Kettering Cancer Center · USMigration Institute of Australia · AUQIMR Berghofer Medical Research Institute · AUUniversity of Michigan · USUniversity of Regina · CAUniversity of Southern California · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
CIHRNCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectivesResearch examining survival among people with ovarian cancer following use of statins or β-blockers has been conflicting. Many studies to date have suffered from immortal time bias and/or had limited power. To address these limitations, we used time-dependent analyses to study the association between statin or β-blocker use among all people diagnosed with an epithelial ovarian cancer in British Columbia, Canada between 1997 and 2015.

methodsPopulation-based administrative data were linked for 4207 people with ovarian cancer. Statin or β-blocker use was examined using time-dependent variables for any use, cumulative duration of use and by user-group according to whether use was initiated before or after their ovarian cancer diagnosis. Cox proportional hazards models were run to estimate the association between statin or β-blocker use and survival.

resultsAny postdiagnosis use of statins was associated with better ovarian cancer survival in the full cohort (adjusted hazard ratio (aHR) = 0.76, 95% CI 0.64, 0.89) and among women with serous cancers (aHR = 0.80, 95%CI 0.67-0.96). This was primarily driven by new use post-diagnosis (aHR = 0.67, 95%CI, 0.51-0.89), but there was a trend towards better survival among those who continued use from before diagnosis (aHR 0.83, 95%CI, 0.68-1.00). There was no statistically significant association between β-blocker use and survival.

conclusionPostdiagnosis statin use was associated with improved survival among people with ovarian cancer. Given the consistency of this finding in the literature, we recommend a randomized clinical trial of statin use in people with ovarian cancer.

Indexed as

Administrative Claims, HealthcareAdrenergic beta-AntagonistsAgedBritish ColumbiaCarcinoma, Ovarian EpithelialCardiovascular DiseasesDrug PrescriptionsFemaleFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMiddle AgedOvarian NeoplasmsRetrospective StudiesSurvival AnalysisAdrenergic beta-AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsBeta-blockersOvarian cancerStatinsSurvival

Identifiers

PMID34090707
PMCPMC9398205
OpenAlexW3169489091

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.